Moderna, Inc. — Director's Dealing 2018

Dec 7, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2018-12-07

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	204770	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$19.15	2026-08-10	Common Stock (483302)		Direct
Stock Option (Right to Buy)	$12.21	2027-02-23	Common Stock (183486)		Direct
Stock Option (Right to Buy)	$12.21	2027-10-03	Common Stock (458715)		Direct
Stock Option (Right to Buy)	$14.22	2028-02-28	Common Stock (160550)		Direct

Footnotes

F1: The 204,770 shares reported in this column are subject to a restricted stock grant dated August 10, 2016, which vests as follows: 25% of the Shares to vest on the first anniversary of the vest start date of March 16, 2015, and the remainder vests in 12 quarterly installments.

F2: 25% of this option vested and became exercisable on March 16, 2016, with the remainder vesting in 12 equal quarterly installments thereafter.

F3: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

F4: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

F5: 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.